Search Clinical Trials
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (External Link)
Approximately 118-27 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (approximately 12 tablespoons) is collected from patients to grow the T cells …
Baylor Role:
Lead Sponsor
Terminated
Ketamine in Veterans With Gulf War Illness (External Link)
Recruitment for this study starts after protocol approval by the BCM IRB, MEDVAMC R&D, and DoD HRPO. All study procedures are for research only. Potential subjects will be recruited (i) …
Baylor Role:
Lead Sponsor
Recruiting
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (External Link)
Transitioning from busulfan, hydroxyurea, IFN-α to tyrosine kinase inhibitors (TKIs) has dramatically altered the natural history of CML. Patients with CML appropriately managed with TKIs are able to benefit from …
Baylor Role:
Lead Sponsor
Withdrawn
Peppermint Oil Pharmacokinetics/Dynamics (External Link)
An initial single-dose PK study will be carried out. Forty-two children (n=21 per dose) will be randomized to receive approximately 10.9 mg·kg-1·d-1 of PMO or to receive approximately 18.2 mg·kg-1·d-1 …
Baylor Role:
Lead Sponsor
Recruiting
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (External Link)
Earlier, a healthy donor provided blood to make ANCHOR cells in the laboratory. These cells were grown and frozen for later use. To make the ANCHOR cells, the investigators took …
Baylor Role:
Lead Sponsor
Recruiting
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) (External Link)
To prepare the brain cancer specific GD2-C7R T cells, research staff will take some blood from the patient. The researchers will grow the GD2.C7R T cells by infecting the T …
Baylor Role:
Lead Sponsor
Withdrawn
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (External Link)
A maximum of 42 subjects will participate in the treatment part of this study. The investigators will collect up to 180 mL of the participants blood. The investigators will use …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (External Link)
To prepare the T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with …
Baylor Role:
Lead Sponsor
Completed
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (External Link)
A maximum of 30 subjects will participate in the treatment part of this study. Up to 180ml of blood is collected from patients to grow the T cells. The T …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (External Link)
Approximately 18-30 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role:
Lead Sponsor